Levemir (insulin detemir) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat high blood sugar levels in ...

Diabetes patients say they will be harmed by Novo Nordisk's decision to phase out the long-acting insulin Levemir. ... Lantus lasts 24 to 36 hours, and Tresiba lasts up to 42 hours.

"Levemir’s action profile makes it perfect for patients who need to make rapid and continual changes," she went on. "An insulin such as Lantus or Tresiba, which the industry tells us to ‘just ...

The companies also hope to steal market share from Novo Nordisk, undercutting the long-acting Levemir (insulin detemir) by 21% and Tresiba (insulin degludec) an ultra long-acting insulin, by 28%.

Senators demand answers from drugmaker about discontinuation of popular insulin Levemir. ... Two other, long-acting "basal" insulins on the market include Sanofi's Lantus and Novo Nordisk's Tresiba.

Three U.S. Senators say they are "alarmed" Novo Nordisk discontinued U.S. sales of a popular insulin brand and are demanding answers from the pharmaceutical giant they say left patients without an ...

Health policy experts say Eli Lilly's competitors—Sanofi, which makes Apidra and Lantus, and Novo Nordisk, which makes NovoLog and Levemir—are now facing increasing pressure to respond.

Novo Nordisk's decision has been criticized by some patients with Type 1 diabetes who prefer Levemir over other long-acting "basal" insulins such as Sanofi's Lantus and Novo Nordisk's Tresiba.